Advanced colorectal cancer: Quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil

Anticancer Research

Volumn 20, Issue 1 B, 2000, Pages 501-504

  Bogliolo, Giuseppe ^a,b   Pannacciulli, Ivo ^a   Desalvo, Luigi ^b   Barsotti, Bianca ^a   Lerza, Roberto ^a   Mencoboni, Manlio ^a   Arboscello, Eleonora ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

5 FU continuous infusion; Advanced colorectal cancer; Quality of life

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFUSION PUMP; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; QUALITY OF LIFE;

ADENOCARCINOMA; AGED; AMBULATORY CARE; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW DISEASES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; NEOPLASM METASTASIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034073144     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Palmeri S and Leonardi V: Colorectal cancer: biological aspects, prognosis related and follow-up. Tumori (Suppl) 83, No 1: S21-S22, 1997.
2. O'Dwyer PJ, Ryan LM, Valone FH et al: Phase III trial of biochemical modulation of 5-Fluorouracil by i.v. or oral leucovorin or by interferon in advanced colorectal cancer. Proceedings ASCO 15: 207, 1996.
3. Machover D, Diaz-Rubio E, De Gramont A et al: Two consecutive phase 2 studies of oxaliplatin (L-OHP) treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98, 1996.
4. Rouger R, Bugat R, Douillard JY et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997.
5. Logue JP, Kiltie AE, James RD et al: Continuous infusion of 5-fluorouracil in patients with progressive metastatic colorectal carcinoma following intermittent 5-FU based chemotherapy. Proc Am Soc Clin Oncol 14: 505, 1995.
6. Wolmark N, Rockette H, Fisher B et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical adjuvant Breast and Bowel Protocol C-03. J Clin Oncol 11: 1979-1987, 1995.
7. O'Connell M, Mailliard J, Mac Donald J et al: An intergroup trial of intensive course 5-FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proc Am Soc Clin Oncol 12: 190, 1993.
8. Erlichman C, Marsoni S, Seitz J et al: Event free and overall survival is increased by FUFA in resected B e C colon cancer: a prospective pooled analysis of 3 randomized trials. Proc Am Soc Clin Oncol 15: A 562, 1994.
9. International multicentre pooled analysis of colon cancer trial (impact): efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939-944, 1995.
10. Froncini G, Petrioli R, Lorenzini L et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106: 899-906, 1994.
11. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation. J Clin Oncol 15: 368-381, 1997.
12. Kemeny N, Nidzwiecki D, Reichman B et al: Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Cancer 63: 1065-1069, 1989.
13. Lokich J, Ahlgren J, Gullo J et al: A prospective randomized comparison of continuous infusion fluorouracil with conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432, 1989.
14. Ardalan B, Singh G, Silberman: A Randomized phase I and II study of short term infusion of high-dose fluorouracil with or without n-(phosphonacetil)-1-aspartic acid in patients with advanced pancreatic and colorectal cancer. J Clin Oncol 6: 1053-1058, 1988.
15. Weinerman B, Shah A, Fields A et al: A randomized trial of continuous systemic infusion vs bolus therapy with 5-fluorouracil in metastatic measurable colorectal cancer. Am J Clin Oncol 15: 518-523, 1992.
16. Levi FA, Zidoni R, Vannetzel JM et al: Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutial trial. J Natl Cancer Inst 86: 1608-1617, 1994.
17. Trump D, Egorin M, Forrest FA: Pharmacokinetic and pharmacodynamic analysis of 5-fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 11: 2027-2037, 1991.
18. Haller DG, Leopoulon M, McDonald JS et al: Some consideration concerning the dose and schedules from the intergroup colon adjuvant trial (INT-0089). Adv Med Biol 339: 51-54, 1993.
19. Nobile M, Vidili M, Sobrero A et al: 5-fluorouracil (5-FU) alone or combined with high dose folinic acid (FA) in advanced colorectal cancer patients. A randomized trial. Proc Am Soc Clin Oncol 7: 97, 1988.
20. Ardalan B, Chua L, Tian EM et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-630, 1991.
21. Zalcberg J, Kerr DJ, Seymour L et al: Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Cancer 34, 12: 1871-1875, 1998.
22. Poon MA, O'Connel MJ, Moertel C et al: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal cancer. J Clin Oncol 7: 1407-1408, 1989.
23. Minsky BD: Multidisciplinary case teams: an approach to the future management of advanced colorectal cancer. Br J Cancer 77 (suppl. 2): 1-4, 1998.
24. Anderson H, Palmer MK: Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience for two recent large phase III trials. Br J Cancer 77 (suppl. 2): 9-14, 1998.